It is a clinical trail to observe the efficacy of two drugs(morphine and ketorolac) in severe vaso occlusive pain crisis(pain management) in sickle cell disease children.

Intravenous Ketorolac versus intravenous Morphine for the management of severe vaso-occlusive crisis in children with sickle cell disease. A randomized controlled trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030300

Enrollment

Registered

2021-01-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D570- Hb-SS disease with crisis

Interventions

Intervention1: ketorolac: ketorolac infusion o.o8mg/kg/hr to 0.17mg/kg/hr to compare with morphine 0.04mg/kg/hr to 0.07mg/kg/hr and infusion rates will be increased by every 3rd hourly. Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: All children diagnosed with severe vaso occlusive crisis sickle cell disease aged 3 To 15 years.

Exclusion criteria

Exclusion criteria: children with age less than 3 years and age more than 15years.

Design outcomes

Primary

Measure	Time frame
pain score will be evaluated every 3rd hourly after starting of infusion ,if anytime pain score less than or equal to 6 for next 6 hours on same infusion rate is considered as responders.Timepoint: 3,6,9,12hours of infusion	—

Secondary

Measure	Time frame
if pain score greater than 6 hours even after 12 hours of infusion, they considered as non respondersTimepoint: 3,6,12 hours.	—

Countries

India

Contacts

Public ContactMukamalla Sai Pratap Reddy

AIIMS, Raipur

akgoel@aiimsraipur.edu.in7674079395

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026